From August 13th to 15th, Mevos International Congress of Aesthetic Surgery and Medicine (Summer 2020) gathering global leaders in the plastic surgery industry, was held at Hangzhou International Expo Center. Mr. Shen Jing, CEO of Singclean Medical, was invited by Professor Cui Haiyan, Editor-in-Chief of ASJ (Aesthetic Surgery Journal) Chinese Edition and delivered a speech as Singderm®, the innovative dermal filler developed by Singclean was launched at the congress. In the practical teaching of beauty injection, Singderm® was used by experts and professors such as Cui Haiyan, Wu Sufan, Song Weimin for demonstration.
Mr. Shen Jing, CEO of Singclean Medical (second from left)
At the Mevos International Congress of Aesthetic Surgery and Medicine (Summer 2020), the Chinese edition of ASJ, the world's leading journal in the fields of aesthetic surgery and cosmetic treatments held a launch ceremony.
And Singderm® was on the first issue of ASJ Chinese edition since she has won widespread praise
from plastic surgery doctors and clients.
Mr. Shen said in his speech that in the next five years, Singclean plans to invest more than 280 million dollars (2 billion yuan) to establish 4-6 science laboratories across China, work with professionals, scholars and medical aesthetics institutes to establish more provincial and ministerial-level projects and publish SCI articles. We look forward to working hand in hand with more outstanding experts and medical and aesthetic institutions to do more high-quality scientific research and academic research for the industry.
On August 12, Professor Wu Sufan and Professor Song Weimin did the facial aesthetic injection training with Singderm in the "VR+AR+3D" skin aesthetics injection practical training class of this conference.
On August 15, Professor Cui Haiyan and Dean Tao Lin took facial injection and thread carving beauty anatomy practice with Singderm®.
Singderm project begun in 2015. Singclean Medical launched international cooperation in scientific research with Novozymes and TAK, two Danish companies, built a controllable and adjustable cross-linking technology platform, and then realized SingLink® patented cross-linking technology .
Singderm, a whole new generation, 24 mg/ml hyaluronic acid-based dermal filler is mono-phasic and contains 0.3% lidocaine. It is result of the international cooperation of special project (No.2015DF51010), and has won support of Fund of the Ministry of Science and Technology. Singderm has passed 12-month clinical verification in three tier 3 hospitals with high stability, safety and effectiveness. Singderm obtained CFDA certification early this year.